Multiple Sclerosis Resource Centre
  • Home
  • MSRC Grand Opening 30/05/12
  • About MS
  • MSRC Services
  • Get Involved
  • MS Research News
  • MSRC Groups
  • Useful Resources
  • Welcome To Josephs Court, MS Centre Of Excellence
  • Advertising
  • Best Bet Diet Group
  • E-Newsletter
  • Contact Us
  • Investor in People
    You are here : Home » MS Research News » New Discoveries » HDL

    HDL

    A A A
    [Print this page]

    Share |


    'Good Cholesterol' May Help Decrease MS Inflammation, Lessen Disability

    HDL

    Could HDL, the "good cholesterol," have the same protective effect in multiple sclerosis, an inflammatory disease of the brain's white matter, as it does in heart disease, through its anti-inflammatory effects on blood vessels?

    The answer may be yes, based on results of research conducted at the University at Buffalo and presented today (Tuesday, April 28) in a poster session at the American Association of Neurology meeting in Seattle, Wash.

    Allison S. Drake, MSc, a researcher in the Jacobs Neurological Institute (JNI), UB's Department of Neurology, is first author on the study.

    Bianca Weinstock-Guttman, M.D., UB associate professor of neurology and director of the JNI's Baird Multiple Sclerosis Center, initiated and oversaw the research.

    "We set out to evaluate the relationship between high-density lipoprotein (HDL) levels and disability in patients with MS," said Drake. "The protective effects of HDL in cardiovascular disease have been well established, but the role of HDL in MS had not been investigated.

    "We found that patients with greater disability (assessed using the physician-reported Expanded Disability Severity Score, EDSS) were more likely to have low HDL blood levels, while those with less disability had higher HDL levels," said Drake, "demonstrating a significant association between HDL level and disability.

    "While it appears that the anti-inflammatory effect of high HDL may be protective in patients with MS, further studies on the relationship between HDL levels, disease modifying therapy and MS disease progression are warranted," she noted.

    The study involved 186 MS patients with average age of 50 who were enrolled in the New York State Multiple Sclerosis Consortium, an alliance of treatment centers throughout the state organized to assess prospectively the clinical characteristics of MS patients. The JNI is the lead site.

    Drake and colleagues had access to the patient's clinical information and HDL levels that were collected when participants entered into the study, and compared that data with measures of disability after an average of 5 years. Patients were classified as having an HDL level of 40 or less, the low level, or 60 or above, the high level, when they were enrolled in the study. (HDL is measured in milligrams-per-deciliter, or mg/dL).

    Results showed that the degree of disability at baseline was significantly associated with HDL level. Specifically, participants with higher EDSS scores at baseline, indicating more disability, were more likely to have lower HDL levels than participants with less disability.

    Additional contributors to the study were Arielle Kurzweil, Murali Ramanathan, Barbara Teter, Terry Justinger, Frederick E. Munschauer and Cornelia Mihai, all from the JNI/UB.

    Source: University of Buffalo © 2009 University at Buffalo. (28/04/09)

    Related Items
    Abnormal Liver Tests and MS
    AlphaB-crystallin
    Aluminium and Multiple Sclerosis
    Antagonist compounds
    Antibodies, B Cells,T-Cell Activation, Immune Response
    Apolipoprotein D
    Bacteria & MS
    Biomarkers and MicroRNA
    Blood tests
    Bone Marrow Cells and MS Treatment
    Bowmann-Birk Inhibitor Concentrate (BBIC)
    Brain Atrophy, Lesion Loads, White and Grey Matter
    Brain Inflammation
    Brain Iron Deposits
    Calcium Binding Proteins
    Cerebro-Spinal Fluid & Spinal Cord
    Chronic Cerebrospinal Venous Insufficiency (CCSVI)
    CRMP-2
    CXCL1, 7, 12
    Cytokines & Chemokines
    Dendritic Cells
    Estrogen Receptors
    Fibrinogen, Mac-1 and Microglia
    HERV-Fc1
    Histamine and MS
    Hormones And MS Research
    Immunoglobulins
    Infections and Multiple Sclerosis Relapses
    Interleukin-1beta
    JAK-STAT inhibitors
    Kallikrein 6
    Lipids & MS
    Medical Imaging
    Mycoplasmas And Bacteria
    N-acetylglucosamine (GlcNAc) & Glucosamine
    Natural Interferon Beta
    Natural Killer Cells
    Nerve and Brain Cell Research
    Neurosteroids
    Olig 1 Gene Discovery
    Oligodendrocytes and Astrocytes
    Pesticides and Multiple Sclerosis
    PKC-theta
    Plasma Exchange
    Potential Viral Causes of MS
    Proteomics
    Recombinant Human Erythropoietin
    Regeneration Research
    RNA and RNAi
    Synthetic Small Molecules
    Technology
    Tetanus Vaccine and Possible MS Protection
    Tetramers
    The Blood Brain Barrier
    Tremors And MS
    Uric Acid
    Urinary Problems
    Vascular Function And MS
    Vision and MS


    Did you find this information useful? Would you like to comment on this page? Let us know what you think! We welcome all comments and feedback on any aspect of our website - please click here to contact us.